New cocktail aims to stall lung Cancer's return
NCT ID NCT07376499
First seen Jan 29, 2026 · Last updated Jun 09, 2026 · Updated 19 times
Summary
This study tests whether a combination of drugs (irinotecan liposome, platinum, an immune checkpoint inhibitor, and anlotinib) can help keep extensive small cell lung cancer from growing after initial treatment. About 31 adults with this aggressive lung cancer will receive the drug combo as maintenance therapy. The goal is to see if this approach extends the time before the cancer progresses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.